Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis

Next Previous
X
Search
Trial Profile

A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms BE ACTIVE
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 13 Jul 2022 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study published in the Arthritis and Rheumatology
    • 05 Jul 2022 Results reporting long-term effects of bimekizumab treatment, up to 3 years on patient-reported outcome (PRO) measures, symptoms and impact of disease in patients with psoriatic arthritis from BE ACTIVE and its open-label extension published in the Rheumatology.
    • 09 Nov 2021 Results from NCT02969525 and NCT03347110 assessing long-term impact of Bimekizumab treatment, up to 3 years, on pt-reported outcome measures, presented at the ACR Convergence 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top